Syngene is a fully integrated CRAMS company and Biocon has around 70% stake in it. Syngene also has a wholly-owned subsidiary in the US.

Fights over succession planning or individual investment decisions can pull a family apart.

The MSCI India 10/40 Index is designed to measure the performance of the largecap and midcap segments of the Indian equity market.

The move reinforces the fact that high-yielding Indian securities are attracting global investors' fancy amid economic gloom in developed c...